Immunomodulatory approaches such as GRI-0621 (RARβγ agonist targeting iNKT activity) may support alveolar basement membrane repair and provide complementary biology for oral combination regimens.
Trevi Therapeutics has made significant strides in its development program for Haduvio, a treatment aimed at addressing ...
The latest conference call transcript from ClearPoint Neuro, Inc. reveals a promising outlook for the company's future growth ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results